Transplant teams should consider using a broader range of donor organs in select pediatric patients. Further interventional research on peritransplant thromboprophylaxis and fluid management is needed to optimize management strategies. The completion of ongoing belatacept and letermovir trials have the potential to substantially alter posttransplant standards of care.
Rachel M. Engen (Mon,) studied this question.